Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GV-108 and GV-907 in Preventing Glioblastoma Recurrence
NCT07520214Phase 1Enrolling by invitation
- Sponsor
- Beijing Neurosurgical Institute
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GV-108 and GV-907 in glioblastoma (GBM) (3 arms), sponsored by Beijing Neurosurgical Institute. Primary endpoints: Adverse Events up to 96 weeks and Antigen-specific T cell responses in peripheral blood at Week 96. Started Sep 2025; status: enrolling by invitation.
02
Drugs
GV-108GV-907
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07520214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07520214.